Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study

Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study

Abstract Background Currently, there are two antifibrotics used to treat idiopathic pulmonary fibrosis (IPF): pirfenidone and nintedanib. Antifibrotics slow disease progression by reducing the annual decline of forced vital capacity (FVC), which possibly improves outcomes in IPF patients. During tre...

Full description

Bibliographic Details
Main Authors: Yuzo Suzuki, Kazutaka Mori, Yuya Aono, Masato Kono, Hirotsugu Hasegawa, Koshi Yokomura, Hyogo Naoi, Hironao Hozumi, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa, Yutaro Nakamura, Naoki Inui, Hidenori Nakamura, Takafumi Suda
Format: Article
Language:English
Published: BMC 2021-07-01
Series:BMC Pulmonary Medicine
Subjects:
Antifibrotic therapy
Idiopathic pulmonary fibrosis
Switch of antifibrotics
Online Access:https://doi.org/10.1186/s12890-021-01587-3

Internet

https://doi.org/10.1186/s12890-021-01587-3

Similar Items